Literature DB >> 7912392

Magnetic resonance imaging of the brain in phenylketonuria.

M A Cleary1, J H Walter, J E Wraith, J P Jenkins, S M Alani, K Tyler, D Whittle.   

Abstract

Abnormalities of magnetic resonance imaging (MRI) of the brain occur in some patients with phenylketonuria but the clinical importance of this finding is not clear. In order to determine the frequency and functional significance of changes on MRI we investigated 77 adolescent and adult patients with phenylketonuria. Patients aged 14-49 years and taking a restricted diet of 1 g/kg protein underwent clinical examination, IQ testing, neurophysiological investigation, and MRI of the brain. Patients aged between 10-14 years taking a low phenylalanine diet with amino acid supplements had MRI of the brain only. Biochemical control was assessed from: the lifetime blood phenylalanine determined from the mean blood concentration throughout life; the accumulated time for each patient that phenylalanine was < 120 mumol/L; the accumulated time for each patient that phenylalanine was > 1200 mumol/L); mean blood concentration in the first 4 years of life; and the mean blood phe concentration in the 5 years prior to imaging. MRI changes, compatible with a disturbance in the water content of white matter, were present in all but 1 patient. The severity of abnormality was most strongly associated with the blood phenylalanine concentration at the time of imaging. Clinical and neurophysiological abnormalities were less common and usually mild. 3 patients had prolonged central motor conduction time, 7 had prolonged visual evoked potentials, and 5 had impaired peripheral sensory nerve conduction. There was no significant association between the extent of MRI abnormalities and IQ, and the presence of neurophysiological, or clinical abnormalities. An abnormal brain scan in PKU may reflect present biochemical control rather than indicate significant neurological damage. As yet there is little evidence that in most patients with PKU these MRI changes are of clinical importance.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7912392     DOI: 10.1016/s0140-6736(94)91281-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  36 in total

1.  Decreasing choline signal--a marker of phenylketonuria?

Authors:  M Dezortová; L Hejcmanová; M Hájek
Journal:  MAGMA       Date:  1996 Sep-Dec       Impact factor: 2.310

2.  Studies of multimodal evoked potentials in treated phenylketonuria: the pattern of vulnerability.

Authors:  A C Ludolph; U Vetter; K Ullrich
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

3.  Complete reversal of moderate/severe brain MRI abnormalities in a patient with classical phenylketonuria.

Authors:  J H Walter; F White; J E Wraith; J P Jenkins; B P Wilson
Journal:  J Inherit Metab Dis       Date:  1997-07       Impact factor: 4.982

4.  Phenylketonuric patients decades after diet.

Authors:  R O Fisch; P N Chang; S Weisberg; P Guldberg; F Güttler; M Y Tsai
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

5.  Tract-based evaluation of white matter damage in individuals with early-treated phenylketonuria.

Authors:  Huiling Peng; Dawn Peck; Desirée A White; Shawn E Christ
Journal:  J Inherit Metab Dis       Date:  2013-09-17       Impact factor: 4.982

6.  Subclinical visual impairment in phenylketonuria. A neurophysiological study (VEP-P) with clinical, biochemical, and neuroradiological (MRI) correlations.

Authors:  V Leuzzi; S Rinalduzzi; F Chiarotti; P Garzia; G Trasimeni; N Accornero
Journal:  J Inherit Metab Dis       Date:  1998-06       Impact factor: 4.982

7.  Developmental timing of exposure to elevated levels of phenylalanine is associated with ADHD symptom expression.

Authors:  Kevin M Antshel; Susan E Waisbren
Journal:  J Abnorm Child Psychol       Date:  2003-12

8.  Long-term follow up of patients with classical phenylketonuria after diet relaxation at 5 years of age. The Paris Study.

Authors:  F Rey; V Abadie; F Plainguet; J Rey
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

9.  Magnetic resonance imaging of the brain in adolescents with phenylketonuria and in one case of 6-pyruvoyl tetrahydropteridine synthase deficiency.

Authors:  J Pietz; U K Meyding-Lamadé; H Schmidt
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

10.  Phenylketonuria: treatment in adolescence and adult life.

Authors:  D P Brenton; A C Tarn; J C Cabrera-Abreu; M Lilburn
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.